BusinessSummit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMDBy Nasdaq OMXJan 21, 2016, 12:00 PM UTC
BusinessFibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXJan 6, 2016, 10:47 PM UTC
